<DOC>
	<DOCNO>NCT02747290</DOCNO>
	<brief_summary>This open-label positron emission tomography/computed tomography ( PET/CT ) study investigate diagnostic performance evaluation efficacy 68Ga-NOTA-BBN-RGD prostate cancer patient . A single dose 111-148 Mega-Becquerel ( MBq ) 68Ga-NOTA-BBN-RGD injected intravenously . Visual semiquantitative method use assess PET/CT image .</brief_summary>
	<brief_title>68Ga-NOTA-BBN-RGD PET/CT Prostate Cancer Patients</brief_title>
	<detailed_description>Both GRPR integrin αvβ3 overexpressed neoplastic cell human prostate cancer . To target receptor , heterodimeric peptide BBN-RGD synthesize bombesin ( 7-14 ) c ( RGDyK ) glutamate linker label 68Ga . An open-label whole-body PET/ CT study design investigate safety dosimetry 68Ga-NOTA-BBN-RGD diagnostic performance 68Ga-NOTA-BBN-RGD PET/CT patient primary and/or metastasis prostate cancer .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Must able provide write informed consent , needle biopsy diagnose prostate cancer , undergone whole body bone scan , able provide basic information sign write informed consent . The exclusion criterion include claustrophobia , kidney liver failure , inability fulfill study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>BBN-RGD</keyword>
	<keyword>PET</keyword>
	<keyword>integrin αvβ3</keyword>
	<keyword>GRPR</keyword>
</DOC>